Introduction
Since the first report that primary mouse muscle cells were able to regenerate dystrophic mouse muscle, a substantial effort has been made exploring the isolation of the best myogenic stem cells, able to repair or replace dystrophic skeletal muscle fibres and to give rise to a muscle stem cell reservoir that persists for a lifetime. To date, many stem cell sources have been investigated and suggested as potentially therapeutic cells. This review aims to summarize and discuss the results of recent studies, highlighting their relevance to a therapeutic approach.
Regeneration of skeletal muscle
Skeletal muscle is the largest tissue in the human body, responsible for posture, movement and breathing. It is composed of bundles of myofibres, the contractile muscle units, each of which contains hundreds of syncytial postmitotic myonuclei. Enclosed between the sarcolemma and basal lamina surrounding each myofibre are found one or more quiescent cells, defined as satellite cells [1 ] . Even though the nuclear turnover of adult skeletal muscle is normally low [2] , in response to disease or injury muscle regeneration occurs as an extremely efficient and rapid process, mediated by satellite cells. Once activated, satellite cells divide to produce muscle precursor cells (MPCs) that proliferate, before committing to differentiation and fusing into myotubes, which finally mature into myofibres [3 ] . A few satellite cells adhered to a single myofibre are able not only to regenerate more than 100 myofibres, but also to maintain the satellite cell compartment [4] .
Muscular dystrophies
The maintenance of muscle function and mass is extremely important to preserve healthy muscle tissue [5] . In pathological muscle, the lack of components of the dystrophin-associated protein complex (DPC), that connects the cytoskeleton of the myofibre to the basal lamina, causes devastating disorders. In particular, in the genetic muscle diseases called dystrophies, the absence of DPC leads to sarcolemma fragility, muscle weakness, necrosis and fibrotic adipose tissue substitution [6] .
There are different types of muscular dystrophy, which affect skeletal muscle tissue with different levels of severity [6] . Among them, the most common is Duchenne muscular dystrophy (DMD), characterized by the lack of dystrophin in myofibres.
Stem cells to treat muscle diseases
The main properties of stem cells, the self-renewal ability and the capacity of multilineage differentiation, allow the development and the maintenance of tissues during postnatal turnover and their regeneration following damage. Stem cells can be isolated from both adult and embryonic tissues, with different abilities to give rise to multiple cell lineages. In the past, many stem cell populations have been explored for their potential to treat muscle dystrophy, but the majority of them have shown poor success [7] . A stem cell, in order to efficiently treat this pathology, must either repair necrotic muscle fibres and produce sufficient dystrophin within these fibres to prevent subsequent necrosis, or replace muscle fibres that have already been lost with new, dystrophin-positive, fibres. Although endogenous satellite cells do contribute to regeneration within dystrophic muscle, their function becomes lost with time. Donor stem cells must therefore also replenish the host satellite cell compartment with functional stem cells. In the dystrophin-deficient mdx mouse, the genetic and biochemical homologue of DMD, mouse satellite cells directly injected into host muscles have been shown to regenerate skeletal muscle and reconstitute the satellite cell pool [4] . Different stem cells may require different ways of delivery. Even though intramuscular injection has been performed in many cases, systemic delivery is the most effective at distributing the donor cells throughout the entire organism. Following intravenous injection, cells may be trapped in organs like liver, spleen and lung, so that only a small number enter the muscle capillary network and thence the dystrophic muscle. Intra-arterial injection, however, leads to donor stem cells having widespread distribution to skeletal muscles through the muscle capillary network [8] .
Stem cell with myogenic potential
It was reported for the first time in 1989 that transplantation of cells derived from normal donor mice could restore the expression of dystrophin in nude/mdx mouse muscle fibres [9] . These early studies, however, used cells obtained by enzymatically disaggregating donor muscle, which would give a population including all the cells present within skeletal muscle: satellite cells, cells coming from the muscle vessels, cells resident in the interstitial space or enrolled from the circulation [9] , cells that are not myogenic, like fibroblasts, and cells that today are known for their myogenicity and stem potential, like muscle-derived stem cells (MDSCs). Interestingly, in those early experiments freshly prepared, noncultured cells were used.
After that, research focused on the limitations of transplanting cultured donor muscle cells: the rapid death in the first 3 days after transplantation of at least 75% of the transplanted MPCs, the poor migration capability of injected MPCs and the necessity of severe immunosuppression to avoid the rapid rejection of injected cells [1 ] . These drawbacks of MPC transplantation triggered research into other stem cell types that might be able to be delivered systemically and not die following transplantation.
The satellite cell: the principal skeletal muscle stem cell
Even though in the past few years attention has been focused on the myogenic potential of other stem cells, the satellite cell remains the primary skeletal muscle stem cell responsible for the maintenance and repair of adult skeletal muscle [3 ] . Thanks to their stem cell character, satellite cells not only possess mesenchymal plasticity [10,11], but more importantly they are able to self-renew [4] . Although anatomical location is the criterion for identifying satellite cells, and there is not a common antigen able to characterize all cells under the basal lamina of muscle fibres, important findings have increased our knowledge regarding the mechanisms and factors related to the regulation of satellite cells [12 ,13 ] . Furthermore, the use of transgenic animal models is an instrument to characterize satellite cells in their niche (Fig. 1a) , for example, the expression of green fluorescent protein (GFP) driven by regulatory elements of the nestin (NES) gene within mouse satellite cells [14 ] and a panel of cell surface markers can be used to characterize satellite cells [1 ,2,3 ,4,7,15]. Once activated, however, antigen expression on satellite cells changes and the in-vitro expanded MPCs lose part of the original myogenic potential so that the engraftment efficiency significantly decreases [15] . Loss of differentiation capacity and senescence may be partly due to dilution of the stem cell potential by partially differentiated progeny during asymmetric cell division [12 ,16] . Kuang and collaborators have described a mechanism of satellite cell division in the niche that could lead to daughter cells either maintaining the satellite stem cell compartment or committing to muscle differentiation, and have suggested a new fluorescence-activated cell sorting (FACS) method in order to separate this stem cell fraction from other myogenic committed satellite cells [12 ] .
Even though the best results of dystrophin expression in 26-30% of muscle fibres in a muscle of DMD patients have been obtained with repeated local injections of many MPCs [17, 18 ] , this treatment would only be suitable for a few vital muscles and would not be applicable to heart and diaphragm muscles, despite indications that MPC transplantation may give rise to some improvement in heart failure [19] .
Only one study in the past suggested the possibility of delivering MPCs intra-arterially [20] , but this experiment used a rat muscle cell line and there are no subsequent reports in the literature of successful intra-arterial injections of MPCs. The reason for this has been assumed to be the inability of MPCs to cross the endothelial barrier.
Quiescence seems to be the key to effective satellite cell stem cell function. Extremely efficient muscle regeneration has been achieved following grafting of quiescent satellite cells on their parent fibre [4], but also satellite cells removed from the fibre and grafted immediately, without a period in vitro, were extremely efficient at regeneration [4, 15, 21] . These results show that only a small number of quiescent satellite cells is sufficient for a robust muscle regeneration and self-renewal, when grafted into irradiated mdx nu/nu host muscle (Fig. 1b) .
A different strategy has been suggested for muscle targets such as heart and diaphragm, delivering cells seeded on synthetic 'patch' scaffolds [22] [23] [24] . This new approach to MPC transplantation -delivery on a material that maintains the viability of the cells for extended time periods while simultaneously allowing outward migration of the cells to populate surrounding tissue -has been investigated using different adult stem cells [22, 25] . Particular attention has been paid to muscle tissue [24] , which would be expected to benefit from the many proposed advantages of scaffold delivery. Indeed, by means of exogenous materials used to guide the three-dimensional organization of stem cells in engineered tissues, a sort of artificial extracellular matrix can be reproduced ex vivo. Furthermore, by adsorbing specific growth factors, the reproduction of the stem-cell microenvironment or 'niche' could allow adult stem cells to more fully reach their regenerative potential during tissue engineering [25] .
Multipotent stem cells in skeletal muscle
Many other stem cells have been identified (Fig. 1c) , isolated and their contribution to skeletal muscle regeneration evaluated in animal models of muscular dystrophies.
It has been proposed that satellite cells can move between adjacent muscle fibres and therefore stay for some time in the interstitial space during growth and regeneration [26 ] . In addition to these 'satellite' cells located outside their niche, however, a different population of skeletal MDSCs isolated via a preplating technique have been described in the interstitial muscle space [1 ] . This cell population is heterogeneous in terms of expression of CD34 and Sca1 markers, and shows not only mesenchymal plasticity but also haematopoietic potential [27] . They are also capable of contributing to muscle regeneration of mdx mice following their injection either directly into limb muscles, or into the circulation [27] and are more efficient at regenerating skeletal muscle than other adherent skeletal muscle-derived cells [28] . Fascinatingly, male and female MDSCs exhibit different muscle regenerative capacities, cells from female mice having greater myogenic potential. [29] . Although they are easily expanded in vitro and show high differentiative potential and capability to migrate in vivo through the vasculature, they have never been isolated in humans. Furthermore, there was no physiological improvement in MDSC-treated dystrophic mouse muscle, and this, coupled with lack of evidence of their long-term self renewal does not make MDSCs at the moment a candidate cell source to treat DMD [7] .
Cells termed muscle side population can be isolated from the interstitial muscle space, and these cells, distinguished by their efficient efflux of the vital DNA dye Hoescht 33342, can be purified by FACS [30] . After the first demonstration that intravenously injected side population cells partially restored dystrophin expression in mdx mice [30] , another recent study demonstrated that side population cells transduced with a microdystrophin transgene can be delivered also intra-arterially, whether or not mice have been lethally irradiated [8] . Furthermore, the authors demonstrated that cultured muscle side population cells, in contrast to freshly isolated side population cells, can engraft more efficiently in dystrophic muscle after delivery via the femoral artery, but the engraftment levels were still not therapeutic [8] . Even though preliminary studies have been carried out investigating side population cells isolated from human fetal muscle [31] , more work is necessary in order to understand the role of side population cells within the muscle.
Considering the haematopoietic stem cells as the archetypal stem cell, many researchers have focused their attention on a stem cell that could be recruited to the muscle from the circulation or the blood vessels. This is particularly intriguing, since a close relationship exists between satellite cells and cells coming from capillaries, as suggested from their strikingly close in-vivo positions [32] . Indeed cells derived from either the periphery of, or from close proximity to, capillaries and microvesselspericytes, mesoangioblasts, and CD133þ progenitor cells -have been isolated and shown to regenerate skeletal muscle after intra-arterial delivery [1 ] . Pericytes are parietal cells localized under the basal lamina of the microvasculature of human skeletal muscles and have been characterized by molecular markers (Fig. 1) as a different cell population from satellite cells and from endothelial cells [33 ] . Pericyte-derived cells are not myogenic in culture, but they become myogenic in vitro once differentiation is induced [33 ] and, interestingly, can strongly contribute to skeletal muscle regeneration and to satellite cells after intra-arterial delivery into dystrophic mice [33 ] . Although this type of stem cell is a good candidate for muscle therapy, the next step is to determine whether transplanted pericytes can fully reconstitute the satellite cell niche as a real functional stem cell [34] .
Mesoangioblasts, which are distinct from pericytes in that they are vessel-associated cells isolated from the embryonic dorsal aorta in avian and mammalian species, express endothelial markers and exhibit mesodermal phenotypes [35] . Recently, mesoangioblasts have been injected into the bloodstream of golden retriever dystrophic dogs [36 ] , and dystrophin restoration and improvement in muscle function and mobility were claimed [36 ,37] . The isolation from muscle blood vessels, however, cannot exclude the presence of other muscle stem cells and the reported beneficial effects could be a consequence of the immunosuppressive drugs given to these animals, since it has been already reported that anti-inflammatory and immunosuppressive drugs can reduce the severity of muscle dystrophy [38,39 ,40] . Therefore additional studies are required to confirm their possible use in the stem cell therapy for DMD patients.
Circulating cells expressing CD133 have been isolated from peripheral blood, and following intra-arterial injection in dystrophic scid/mdx mice were able to contribute to muscle regeneration [41] . A recent study [42] showed that human dystrophin expression was significantly increased when muscle exercise was performed 24 h before the arterial injection of CD133 positive cells. The acute inflammation produced by muscle exercise increased the expression of vascular cell adhesion molecule (VCAM)-1 on murine endothelium that mediated the efficient recruitment of injected cells [43] . This suggests that manipulating the expression of VCAM-1 and its ligands, thus modifying the homing of injected cells, could be another way of improving muscle cell therapy.
Circulating myogenic precursor cells have been also shown to exist in the bone marrow, but, after the first demonstration of their capability to contribute to muscle regeneration [44] , the low level of incorporation into regenerating muscle fibres and the demonstration that, although they give rise to cells in the satellite cell position, these bone-marrow derived satellite cells are not functional [45] have led to a loss of interest in these cells for stem cell-based muscle therapy.
Engineered embryonic stem cells may represent another therapeutic stem cell source, but research is ongoing to evaluate their real muscle-regenerating capability [1 ,46] . A recent study reported for the first time the intrauterine delivery of human fetal mesenchymal stem cells via intramuscular, intravascular and intraperitoneal routes in fetal dystrophic mdx mice [47] . Although the low-level of chimerism achieved is not curative for DMD [47] , the fetal therapeutic approach could be a possible way for the treatment of genetic muscle diseases [48] .
Finally, for a successful treatment for muscular disease, we need to know not only the optimal cell source, but also the role of the environment and the cues that influence the number and the activity of satellite cells in a pathological situation [13 ] . In particular, a recent paper focused on the fibrotic aspects of muscular dystrophy, suggesting that the fibrotic progression in dystrophic muscle involves changes in the mechanisms controlling matrix production that result in a reprogramming of MPCs to a pro-fibrotic function [49 ] .
Last but not least, a stem cell is characterized by a great proliferative potential and this could cause neoplastic transformation [50] . Therefore, the systemic delivery and the uncommitted state of stem cells have to be considered as powerful but also potentially dangerous tools in stem cell therapy.
Conclusion
Many stem cells are currently being studied in the context of potential stem cell-based therapy for muscle diseases. Encouraging findings suggest that during muscle regeneration many stem cells could be enrolled in the repair process. The relevance of their contribution and their functional properties, however, have to be evaluated. The satellite cell still remains the first protagonist in muscle regeneration. Understanding the most effective way to preserve its myogenic potential once delivered in a damaged muscle tissue and exploring the importance of the pathological environment on its stem character are the main points to be investigated for a successful therapeutic approach.
